DLX 105

Drug Profile

DLX 105

Alternative Names: DLX-105; ESBA-105; Humanised single-chain (scFv) antibody directed against human TNF-alpha

Latest Information Update: 24 Mar 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator ESBATech
  • Developer Cell Medica; Delenex Therapeutics; ESBATech
  • Class Immunoglobulin fragments
  • Mechanism of Action Tumour necrosis factor alpha inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Plaque psoriasis
  • Phase I/II Behcet's syndrome
  • Preclinical Hidradenitis suppurativa
  • Discontinued Age-related macular degeneration; Crohn's disease; Dry eyes; Ocular inflammation; Osteoarthritis; Uveitis

Most Recent Events

  • 12 Jul 2016 Delenex Therapeutics has been acquired and merged into Cell Medica
  • 06 Oct 2015 Discontinued - Phase-I for Osteoarthritis in Germany (Intra-articular)
  • 06 Oct 2015 Discontinued - Phase-I for Osteoarthritis in Switzerland (Intra-articular)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top